publicações selecionadas
-
artigo académico
- Synthesis and Biological Evaluation of Novel Chromeno[2,3-d]Pyrimidinones as Agents for Triple Negative Breast Cancer Treatment. European Journal of Medicinal Chemistry (IF 7.08, Q1 Chemistry, Organic). 2023
- New chromene-based compounds as anticancer agents for triple-negative breast cancer therapy. Euroepan Journal of Medicinal Chemistry. 2022
-
documento
- Biological characterization of novel chromeno[2,3-d]pyrimidinones as therapeutic approach for the treatment of triple-negative Breast Cancer 2023
- Chromene-based molecules: privileged scaffold for oncology drug development 2023
- Synthesis of chromene[2,3-b]pyridines and characterization of their anticancer potential for the treatment of breast cancer 2023
- In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer 2023
- Avaliação in vitro e in vivo de novos cromeno[2,3-d]pirimidinonas como agentes terapêuticos para o cancro da mama triplo-negativo 2023
- Chromen[2,3-b]pyridines: synthesis and evaluation of the anticancer potential for breast cancer treatment 2022
- A new lead compound for triple negative breast cancer therapy 2021
- New chromene derivatives: overcoming renal cell carcinoma drug resistance 2021
- Novel therapy for renal cell carcinoma: overcoming drug resistance 2021